作者: Thomas D. McClure , Karl H. Schram
DOI: 10.1007/978-1-4899-1748-5_5
关键词:
摘要: Conventional diagnosis, disease staging, and evaluation of therapy for cancer acquired immune deficiency syndrome (AIDS) rely heavily on clinically observable measurements rather than biochemical tests. In the case cancer, these include tumor imaging tissue biopsy are accurate only after many cells have been produced as a consequence progression. A diagnosis AIDS is established by detection host-produced antibodies to human immunodeficiency virus (HIV), whereas measurement response therapy, determining type severity opportunistic infections (OI) suffered patients determined T- CD-4 cell populations (1). For both AIDS, methods can be unreliable; also, in some instances, they painful increase risk patient. example, mesothelioma (cancer pleural covering lung, most often result exposure asbestos fiber) an invasive procedure requiring rib resection obtain cytological analysis. dangerous level unreliability detecting HIV infection has observed results long lead time between production antibodies. recent study (2), were shown infected with 35 months before detected. As deficiencies clinical test methods, considerable research effort expended toward finding alternative indicators or “biomarkers” AIDS.